NASDAQ:TMDX TransMedics Group (TMDX) Stock Price, News & Analysis $114.96 -1.76 (-1.51%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$115.46 +0.50 (+0.43%) As of 08/29/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About TransMedics Group Stock (NASDAQ:TMDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TransMedics Group alerts:Sign Up Key Stats Today's Range$112.82▼$117.0550-Day Range$103.61▼$134.0152-Week Range$55.00▼$172.78Volume665,581 shsAverage Volume998,422 shsMarket Capitalization$3.92 billionP/E Ratio59.57Dividend YieldN/APrice Target$123.00Consensus RatingModerate Buy Company Overview TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. Read More TransMedics Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreTMDX MarketRank™: TransMedics Group scored higher than 66% of companies evaluated by MarketBeat, and ranked 348th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingTransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageTransMedics Group has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about TransMedics Group's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth43.00% Earnings GrowthEarnings for TransMedics Group are expected to grow by 43.00% in the coming year, from $1.00 to $1.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is 59.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 270.86.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is 59.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.27.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 12.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TransMedics Group's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.19% of the float of TransMedics Group has been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in TransMedics Group has recently decreased by 4.12%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted24.19% of the float of TransMedics Group has been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in TransMedics Group has recently decreased by 4.12%, indicating that investor sentiment is improving. News and Social Media3.4 / 5News Sentiment1.08 News SentimentTransMedics Group has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for TransMedics Group this week, compared to 13 articles on an average week.Search Interest24 people have searched for TMDX on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.MarketBeat Follows6 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $95,903.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TransMedics Group's insider trading history. Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TMDX Stock News Headlines$100 Invested In TransMedics Group 5 Years Ago Would Be Worth This Much TodayAugust 29 at 5:28 PM | benzinga.comWhat TransMedics Group (TMDX)'s Upward 2025 Earnings Revisions Mean For ShareholdersAugust 28 at 7:49 PM | finance.yahoo.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal. | Brownstone Research (Ad)Needham & Company LLC Reiterates "Hold" Rating for TransMedics Group (NASDAQ:TMDX)August 27, 2025 | americanbankingnews.comA Glimpse Into The Expert Outlook On TransMedics Group Through 4 AnalystsAugust 25, 2025 | benzinga.comTransMedics to Present at Upcoming September Investor ConferencesAugust 25, 2025 | prnewswire.comTransMedics: CEO Is Buying Shares Ahead Of A Potentially Concerning Q3August 25, 2025 | seekingalpha.comZacks Investment Ideas feature highlights: IonQ, Hims and Hers, Eli Lilly and TransMedicsAugust 14, 2025 | finance.yahoo.comSee More Headlines TMDX Stock Analysis - Frequently Asked Questions How have TMDX shares performed this year? TransMedics Group's stock was trading at $62.35 on January 1st, 2025. Since then, TMDX shares have increased by 84.4% and is now trading at $114.96. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) announced its quarterly earnings data on Wednesday, July, 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. The business's quarterly revenue was up 37.7% compared to the same quarter last year. Read the conference call transcript. When did TransMedics Group IPO? TransMedics Group (TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. Who are TransMedics Group's major shareholders? Top institutional investors of TransMedics Group include Geode Capital Management LLC (2.36%), Hood River Capital Management LLC (1.99%), Eventide Asset Management LLC (1.61%) and Marshall Wace LLP (1.60%). Insiders that own company stock include James R Tobin, Waleed H Hassanein, Miriam Provost, Stephen Gordon, Nicholas Corcoran, Tamer I Khayal, John F Carey, Anil P Ranganath, David Weill, Edward M Basile, Laura Damme and Stephanie Lovell. View institutional ownership trends. How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that TransMedics Group investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Broadcom (AVGO), Arista Networks (ANET) and CrowdStrike (CRWD). Company Calendar Last Earnings7/30/2025Today8/30/2025Next Earnings (Estimated)10/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:TMDX CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Price Target for TransMedics Group$123.00 High Price Target$150.00 Low Price Target$75.00 Potential Upside/Downside+7.0%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$1.93 Trailing P/E Ratio59.57 Forward P/E Ratio114.96 P/E GrowthN/ANet Income$35.46 million Net Margins13.49% Pretax Margin13.95% Return on Equity28.02% Return on Assets8.64% Debt Debt-to-Equity Ratio1.61 Current Ratio9.86 Quick Ratio9.17 Sales & Book Value Annual Sales$441.54 million Price / Sales8.88 Cash Flow$1.65 per share Price / Cash Flow69.87 Book Value$9.33 per share Price / Book12.32Miscellaneous Outstanding Shares34,090,000Free Float31,704,000Market Cap$3.92 billion OptionableOptionable Beta2.09 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:TMDX) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.